New drug development : regulatory paradigms for clinical pharmacology and biopharmaceutics
著者
書誌事項
New drug development : regulatory paradigms for clinical pharmacology and biopharmaceutics
(Drugs and the pharmaceutical sciences, v. 141)
M. Dekker, c2004
大学図書館所蔵 全4件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
内容説明・目次
内容説明
Highlighting key points from the latest regulatory requirements, New Drug Development helps those new to the world of pharmaceutical development understand regulatory steps, reduce cost by avoiding unnecessary trials, and attain guidance through each step of the drug approval process. This volume acquaints readers with procedures that determine the success of drug development projects with updated regulatory guidelines from the FDA and ICH, solutions to hurdles in application protocols, and recommendations from more than 40 respected and experience officials from regulatory agencies around the globe. It covers topics related to the development of chiral drugs, liposomal products, and more.
目次
- Preface Part I History and Basic Principles 1. Introduction to Drug Development and Regulatory Decision-Making 2. Evolution of Drug Development and its Regulatory Process 3. Regulatory Bases for Clinical Pharmacology and Biopharmaceutics Information in a New Drug Application 4. New Drug Application Content and Review Process for Clinical Pharmacology and Biopharmaceutics Part II In Vitro/Pre-Clinical In-vitro Drug Metabolism Studies During Development of New Drugs 6. Drug Transporters 7. Principles, Issues, and Applications of Interspecies Scaling Part III Clinical Pharmacology 8. Analytical Method Validation 9. Studies of the Basic Pharmacokinetic Properties of a Drug: A Regulatory Perspective Perspective 10. Surrogate Markers in Drug Development 11. Population Pharmacokinetic and Pharmacodynamic Analysis 12. Scientific and Regulatory Considerations for Studies in Special Population 13. Conducting Clinical Pharmacology Studies in Pregnant and Lactating Women 14. Scientific, Mechanistic, and Regulatory Issues with Pharmacokinetic Drug-Drug Interactions 15. Assessing the Effect of Disease State on the Pharmacokinetics of the Drug 16. Clinical Pharmacology Issues Related to Specific Drug Classes During Drug Development Part IV Biopharmaceutics 17. Issues in Bioequivalence and Development of Generic Drug Products 18. Regulatory Considerations for Oral Extended Release Dosage Forms and in vitro (Dissolution)/in vivo (Bioavailability) Correlations 19. In vivo Bioavailability/Bioequivalence Waivers 20. Bioavailability and Bioequivalence Issues for Drugs Administered via Different Routes of Administration
- Inhalation/Nasal Products
- Dermatological Products, Suppositories Part V Contemporary and Special Interest Topics 21. Scientific and Regulatory Issues in Development of Chiral Drugs 22. A Regulatory View of Liposomal Drug Product Characterization 23. Challenges in Drug Development: Biological Agents of Intentional Use 24. The Regulation of Antidotes for Nerve Agent Poisoning 25. Bioequivalence Assessment: Approaches, Designs, and Statistical Considerations
「Nielsen BookData」 より